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ABBREVIATIONS
Abl Abelson murine leukemia oncogene
AGM The para-aorta-splanchnopleura region which during development
contributes to the future Aorta, Gonads and Mesonephros
b-ARK b-adrenergic receptor kinase
BCR B cell receptor
BLNK/SLP-65 B-cell linker / SH2-domain-containing leukocyte protein of 65 kDa
Bmx Bone marrow tyrosine kinase gene in chromosome X
BRDG1 BCR downstream signaling 1
Btk Brutons tyrosine kinase
CAP c-Cbl-associated protein
Cbl CysB-like adaptor protein
cDNA Complementary deoxyribonucleic acid
C-terminal Carboxyl-terminal
DAG Diacylglycerol
Dll4 Delta-like ligand 4
DNA Deoxyribonucleic acid
Dok Downstream of tyrosine kinases
EGF Epidermal growth factor
EGFR Epidermal growth factor receptor
Epo Erythropoietin
Erb EGFR related protein tyrosine kinase
Etk Epithelial and endothelial tyrosine kinase (Bmx)
EWS Ewings sarcoma
FADD Fas-associated protein with death domain
FAK Focal adhesion kinase
FERM 4.1 protein, ezrin, radixin, moesin-homology
GADS Grb2-related adaptor downstream of Shc
G-CSF Granulocyte-colony stimulating factor
Grb2 Growth factor receptor bound protein 2
HC Hematopoietic cytokine
Hck Hematopoietic cell kinase
HRG Heregulin
HSC Hematopoietic stem cell
IBtk Inhibitor of Btk
IFNg Interferon g
IL Interleukin
IP3 Inositol 3,4,5-triphosphate
Itk Interleukin-2-inducible T cell kinase
Jak Janus kinase
KD Kinase dead, kinase inactive
KO Knockout
LAT Linker for activation of T cells
MAPK Mitogen-activated protein kinase
MHC Major histocompatibility complex
mRNA Messenger ribonucleic acid
NRTK Non-receptor tyrosine kinase
N-terminal Amino-terminal
Pak1 P21-activated kinase 1
PH Pleckstrin homology
PI-3K Phosphatidylinositol-3-kinase
PIP2 Phosphatidylinositol 4,5-biphosphate
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PIP3 Phosphatidylinositol 3,4,5-triphosphate
PKC Protein kinase C
PLC Phospholipase C
PlGF Placenta growth factor
PTB Phosphotyrosine binding
PTEN Phosphatase and tensin homolog deleted on chromosome 10
PTK Protein tyrosine kinase
PTPase Protein tyrosine phosphatase
pY Phosphotyrosine
Rch1a Karyopherin a
Rho Ras homology gene family
RNA Ribonucleic acid
RTK Receptor tyrosine kinase
Sab SH3-domain binding protein that preferentially associates with Btk
SCF Stem-cell factor
SFK Src family kinase
SH Src homology
SHIP SH2-containing inositol 5-phosphatase
SKAP55 Src kinase-associated protein of 55 kDa
SLP-76 SH2-domain-containing leukocyte protein of 76 kDa
SOS Son of sevenless
Src Rous sarcoma oncogene
SRF Serum response factor
STAT Signal transducer and activator of transcription
Syk Spleen tyrosine kinase
TCR T cell receptor
Tec Tyrosine kinase expressed in hepatocellular carcinoma
TG Transgenic
TGFa Transforming growth factor a
TH Tec homology
Tie Tyrosine kinase with Ig and EGF homology domains
TK Tyrosine kinase
TNFR Tumor necrosis factor receptor
TNFa Tumor necrosis factor a
TPO Thrombopoietin
Txk T cell X chromosome kinase
Vav Vav1 oncogene
VEGF Vascular endothelial growth factor
VEGFR Vascular endothelial growth factor receptor
v-Fps Fujinami avian sarcoma viral oncogene (v-Fes)
WASP Wiskott-Aldrich syndrome protein
WT Wildtype
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ABSTRACT
Development and survival of a multicellular organism is dependent on cell-to-cell
signaling. Cells must be able to communicate with each other and to respond to
extracellular stimuli in an appropriate manner. Signaling between cells takes place
either locally, as a result of a direct contact between cells, or via secreted soluble
signal mediators, both locally acting growth factors and cytokines and systemically
circulating endocrine hormones. For fat-soluble hormones like steroid hormones, the
receptor molecule is usually an intracellular transcription factor. In contrast, soluble
polypeptides, such as growth factors acting on solid tissues and cytokines, mainly
involved in the survival and differentiation of hematopoietic cells, activate membrane
anchored receptor molecules. These receptors initiate a cascade of covalent
phosphorylations culminating in a change in gene transcription events. In
multicellular organisms, phosphorylation, especially on tyrosine residues plays major
roles in transducing signals from the plasma membrane to the cell nucleus. To date,
over 90 protein tyrosine kinases have been identified in the human genome, out of
which at least 32 encode intracellular tyrosine kinases (1).
In this thesis work, one intracellular signal mediator, the Bmx tyrosine kinase,
a member of the Tec gene subfamily, has been studied. The study was undertaken to
identify the expression pattern of the gene as well as to elucidate the function and
signaling properties of the protein in different cell types. We show that among non-
hematopoietic cells, the Bmx gene is almost exclusively expressed in arterial
endothelial cells, with only some expression in epithelial cells. This is the first
example of an intracellular tyrosine kinase showing such restricted arterial expression.
We also identify four receptors, two hematopoietically expressed cytokine receptors
and two endothelial specific receptor tyrosine kinases that activate Bmx. In
hematopoietic cells, Bmx regulates granulocytic differentiation of progenitor cells,
while overexpression of Bmx in skin keratinocytes induces a phenotype characterized
by proliferation and scaling of the skin and induction of inflammation and
angiogenesis. However, mice lacking a functional Bmx gene do not show any
noticeable phenotype, suggesting that members of the Tec family at least to some
extent are redundant.
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REVIEW OF THE LITERATURE
1. THE DEVELOPMENT OF THE CIRCULATORY SYSTEM: COMMON
ORIGINS OF ENDOTHELIAL AND HEMATOPOIETIC CELLS
1.1. Vasculogenesis and angiogenesis
The blood circulation system is the first organ system to function during embryonic
development. The circulatory system is necessary for distribution of oxygen and
nutrients to, and removal of waste products from developing organs and tissues. The
first step leading to the formation of the embryonic vasculature is the induction of the
ventral-lateral mesoderm, which gives rise to cardiac, pronephric, hematopoietic and
vascular endothelial tissues. The hematopoietic and vascular endothelial cell lineages
are thought to be particularly closely related as hemangioblasts, which are aggregated
into blood islands in the yolk sac, can differentiate into both endothelial cells and
primitive hematopoietic cells (Figure 1, for reviews, see (2, 3)). In addition,
differentiating hematopoietic and endothelial cells share several surface markers, such
as CD31 and CD34 (4, 5).
Figure 1.
Schematic
illustration of
mesoderm
differentiation
to endothelial
and
hematopoietic
cells.
Hemangioblasts undergo their first critical step of differentiation within the
blood islands when cells in the center differentiate into primitive hematopoietic stem
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cells, while the cells at the periphery develop into endothelial precursor cells (Figure
1). Following commitment to endothelial cell lineage, the precursor cells, presumably
induced by fibroblast growth factor-2, assemble by vasculogenesis into a primitive
vascular plexus of veins and arteries. The primitive vasculature subsequently develops
into a complex organized and interconnected network via cellular and molecular
mechanisms such as endothelial cell migration, proliferation, differentiation,
extracellular matrix proteolysis, vascular wall remodeling, vessel splitting, fusion,
sprouting and intercalation, collectively called angiogenesis (reviewed in (6)).
1.2. Arteriogenesis, the differentiation of angioblasts to arterial endothelial cells
In adults, arteries and veins are functionally and morphologically distinct, with
different arrangements of supporting cells. In early embryos however, before vessels
have recruited periendothelial support cells, arteries and veins appear similar.
Previously it was thought that a variety of non-genetic mechanisms, for example
blood flow and pressure, could account completely for the structural differences
between the arterial and venous systems. However, recent genetic evidence, mainly
from zebra fish studies, indicate a complex interaction between several signaling
pathways, even prior to both the initiation of circulation and angiogenic remodeling,
as being responsible for arterial endothelial-cell differentiation (7, 8). The first
indication for the existence of arterial and venous specific genes came in 1998 when
Wang et al. published the expression pattern of ephrinB2 ligand and its EphB4
receptor (9). Starting at early embryonic development, ephrinB2 expression is
restricted to arterial endothelial cells. The expression progressively extends to
surrounding arterial smooth muscle cells and pericytes, while EphB4, a receptor for
ephrinB2, marks veins but not arteries (9, 10). Mice lacking the entire ephrinB2
protein (9) or the cytoplasmic domain of ephrinB2 (11) show a similar phenotype
with severe defects in remodeling of both arteries and veins. Since these initial
findings were published, several other artery and vein specific genes have been
reported (Table 1).
Analysis, particularly from zebra fish, has reveled the importance of Notch
signaling in promoting arterial cell fate. The transmembrane Notch receptor was
initially identified in Drosophila melanogaster, but has subsequently been shown to
be important for cell-fate decisions in virtually all animal species that have been
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studied (12). By in situ hybridization, Villa et al. showed that three Notch receptors,
Notch1, Notch3 and Noch4, as well as three Notch ligands, Delta4, Jagged1 and
Jagged2, are expressed in the arteries. Delta4 is endothelial specific, while Notch1,
Notch3, Notch4, Jagged1 and Jagged2 were found to be expressed either in both
arterial endothelial and arterial smooth muscle cells, or only in smooth muscle cells
(13). In addition, Notch ligand Dll4 is expressed specifically in arterial endothelium
(14), while the expression of zebra fish DeltaC ligand in endothelial cells is restricted
to arteries (15).
Gene Species Description Reference
Artery specific
Angiopoietin 2 Chick Tie-2 ligand (16)
Bmx Mouse Intracellular tyrosine kinase (17, 18)
DeltaC Zebra fish Notch ligand (15)
Dll4 Mouse Notch ligand (14)
EphrinB2 Mouse, chick,
zebra fish
Transmembrane Eph ligand / receptor (9, 19, 20)
GridlockA Zebra fish Transcription factor (7)
HeyL Zebra fish Transcription factor (21)
Jagged1 and 2 Mouse Notch ligands (13)
Neuropilin-1 Chick Transmembrane receptor (22)
Notch1, 3 and 4 Mouse Notch receptors (13)
Vein specific
Angiopoietin 1 Chick Tie-2 ligand (16)
EphB4 Mouse, frog,
zebra fish
Transmembrane ephrin receptor / ligand (9, 20, 23)
Neuropilin-2 Chick Transmembrane receptor (22)
Table 1 Markers for arteries and veins (modified from (8))
The only intracellular tyrosine kinase showing high specificity for arterial
endothelium is the Tec family kinase Bmx. The Bmx gene was originally cloned from
a human bone marrow cDNA library (24) and was subsequently found to be
expressed in a subset of hematopoietic cells (25, 26). In non-hematopoietic cells, the
Bmx gene shows striking arterial endothelial specificity with only some minor
expression outside of the vascular system (17, 18). Surprisingly, however, the loss of
the Bmx gene did not affect the growth of arteries (18). The Bmx gene will be
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discussed in more detail later.
1.3. Hematopoiesis
Since the pioneering studies of Florence Sabin in 1920 (27), numerous studies have
shown that blood cells develop in close proximity to the vascular system from a
common progenitor cell population (reviewed in (2)). The first wave of hematopoiesis
occurs in the extra-embryonic yolk sac and it leads to the production of primitive
nucleated red blood cells with a high oxygen delivery capacity (Figure 1, left side).
While this transient embryonic hematopoiesis is still active, another wave of
hematopoiesis, so called definitive hematopoiesis, is initiated within the AGM region
of the embryo (Figure 1, right part. The AGM region; the mesoderm derived para-
aorta-splanchnopleura which gives rise to the future aorta, gonads and mesonephros).
It is not clear whether the definitive hematopoietic stem cells are derived exclusively
from the AGM region by hemogenic endothelial cells that bud hematopoietic stem
cells (HSCs), or whether a true yolk sac hemangioblast giving rise to both endothelial
cells and definitive HSCs exists. In chick, there appears to be no contribution of yolk
sac-derived cells to adult hematopoiesis, but in frogs for example, it has been
estimated that approximately 20% of the adult blood cell population is derived from
the ventral blood island, the yolk sac equivalent (28). Regardless of the origin of the
HSCs, these will eventually provide both the fetus and the adult with all the
hematopoietic stem cells needed. During embryogenesis, the major site for
hematopoiesis is the liver, but in adults, hematopoiesis takes place mainly in the bone
marrow (28, 29). Starting from a common stem cell, every blood cell has to go
through the differentiation steps finally leading to the formation of the eight main
blood cell lineages (Figure 2).
The hematopoietic differentiation process is guided by the function of
hematopoietic cytokines (HCs). The HCs can be divided into two major groups, the
early acting lineage non-specific HCs and the late acting lineage-specific HCs. For
instance, interleukin-3 (IL-3) stimulates the growth of pluripotent progenitor cells, but
does not support their terminal differentiation. In contrast, the late acting HCs, like
erythropoietin (Epo) and granulocyte-colony stimulating factor (G-CSF), are mostly
lineage specific. They not only stimulate proliferation, but also induce terminal
differentiation of hematopoietic cells of particular lineages (reviewed in (30)).
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Although major targets of HCs are cells of the hematopoietic system, cytokines also
have well-defined functions in other cell types. For example IL-1, IL-6, IL-8 and IL-
12, act together with tumor necrosis factor a (TNFa) on endothelial cells causing an
increase in vascular diameter and permeability as well as an upregulation of vascular
adhesion molecules at sites of inflammation (31).
HSC
Lymphoid SCMyeloid SC
Pre-B cell Pre-T cell
B cell T cell
Eosinophil
Mast cell /
basophil
MonocyteGranulocyte
Megakaryocyte
Erythrocyte
Figure 2. Hematopoiesis. Abbreviations used: HSC: hematopoietic stem cell, SC: stem cell
2. CELL SIGNALING: FROM THE CELL SURFACE TOWARDS THE
NUCLEUS
2.1. Protein phosphorylation in cell signaling
Cellular responses such as cell survival, proliferation, differentiation and apoptosis
are dependent on intracellular signaling. The importance of protein phosphorylation
for cell signaling started to emerge nearly 50 years ago with the findings that
reversible phosphorylation can alter the activity of glycogen phosphorylase (32, 33).
It has been estimated that the human genome consists of at least 518 protein kinases,
representing about 1.7% of all human genes (1). In a typical vertebrate cell, around
90% of the proteins are serine phosphorylated compared to tyrosine phosphorylation
of only approximately 0.05% of the proteins. Consequently, tyrosine phosphorylation
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enables a high degree of specificity in cell signaling through regulation of the activity
of tyrosine kinases, as well as the counteracting tyrosine phosphatases, which remove
phosphate groups from target tyrosine residues (34).
2.2. Phosphorylation by tyrosine kinases
In 1979, Eckhart et al first described protein modification by tyrosine phosphorylation
(35) and in 1987, protein tyrosine kinase (PTK) activity was discovered to be
associated with the translational product of the Rous sarcoma virus oncogene, v-src
(36). Since these initial findings it has become clear that crucial cellular signals such
as those for growth, differentiation, adhesion, migration and apoptosis are frequently
transmitted through tyrosine phosphorylation. The enzymes that carry out the
modifications are the protein tyrosine kinases (PTKs), either receptor (RTKs) or non-
receptor (NRTKs, also called intracellular or cytoplasmic) tyrosine kinases. These
enzymes catalyze the transfer of the gamma phosphate of ATP to tyrosine residues on
protein substrates (reviewed in (37, 38)). In contrast to serine/threonine kinase
families, which are conserved throughout eukaryotes, PTKs are generally thought to
be present only in metazoans, even though one potential bacterial tyrosine kinase has
been described (39). So far, over 90 PTKs have been identified in the human genome.
These code for 32 NRTKs grouped into 10 subfamilies (Figure 3) and 58 RTKs in 20
subfamilies. Additional 5 novel human PTKs were recently identified, but these have
not been fully characterized yet (1).
The kinase domain of PTKs is usually around 300 amino acid residues long,
containing several conserved residues. The overall architecture of the TK domain is
similar to serine/threonine kinase domains, consisting of two lobes. The smaller N-
terminal lobe is composed of a five-stranded b-sheet and one a-helix, aC, which
functions in the regulation of the kinase. The C-terminal lobe is mainly a-helical and
responsible for binding of the substrate. The linker region between the N- and C-
terminal lobes forms a cleft at the ATP binding site (37). There is growing evidence
that phosphorylation of tyrosines in the activation loop (A-loop), located in the C-
terminal lobe of the kinase domain, typically leads to an aC mediated conformational
change and an increase in enzymatic activity. This regulation occurs either via trans-
autophosphorylation or via phosphorylation by a different NRTK, for example by Src
kinases in the activation of Tec kinases (discussed in section 3.4). In some cases,
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phosphorylation of tyrosine residues outside of the activation loop might negatively
regulate the kinase activity by introducing intra- and/or intermolecular associations
(40).
Figure 3. Domain organization for the major NRTK subfamilies. The Ack (Ack1 and Ack2)
and Frk (Frk, Brk, Srms) families are not included in the figure. The lengths of the NRTKs
and the domains are only approximately to scale. * Abbreviation: FERM domain; 4.1 protein,
ezrin, radixin, moesin-homology domain. Modified from (37, 38)
2.3. The use of signaling domains for intracellular signaling
Ligand binding to RTKs induces receptor dimerization and activation, presumably by
causing a conformational change of the receptor chains. As a result, the receptor
becomes transphosphorylated on regulatory tyrosines in the activation loop, and
promotes phosphorylation of target protein tyrosines (reviewed in (41)). The
phosphorylated tyrosine residues on the activated receptor serve as docking sites for
proteins containing phosphotyrosine recognition domains (SH2 or PTB) such as
PTKs, PTPases, adaptors, scaffolds, small GTPase signaling proteins, phospholipid
signaling proteins, cytoskeletal regulation proteins, transcription factors etc. These
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proteins convert the extracellular stimuli to a biological response through intracellular
signaling pathways leading to changes in cellular behavior. The use of signaling
homology domains is a general feature; approximately 2.5% of human gene products
contain one or more homology domains (42). It is now clear that specific protein-
protein interactions, such as those mediated by homology domains recognizing pTyr,
pThr/Ser, acetylated/methylated lysine or proline rich sequences and protein-lipid
interactions, mediated by phospholipid binding domains, play essential roles in
signaling from a wide range of surface receptors. These interactions control a number
of cellular events such as protein and vesicle trafficking, cell cycle, gene expression,
DNA repair, reorganization and control of the cytoskeleton and targeted protein
degradation. The use of small, independent protein domains has allowed the evolution
of similar signaling mechanisms for different proteins. This also enables crosstalk
between signaling pathways and creates the possibility for a protein to participate in
several different networks (for reviews, see (43-45)).
3. THE TEC FAMILY OF INTRACELLULAR TYROSINE KINASES
The Tec family of intracellular tyrosine kinases constitutes the second largest family
of NRTKs. The mammalian family consists of five members, the founder member
Tec as well as Btk, Itk/Tsk/Emt, Txk/Rlk and Bmx/Etk. When compared to Src
kinases, the Tec kinases lack both the N-terminal myristoylation signal and the C-
terminal regulatory tyrosine residue. Instead, Tec kinases have two conserved
regulatory tyrosine residues, one in the kinase domain and one in the SH3 domain (the
function of these tyrosine residues in the regulation of Tec kinase activity is discussed
in section 3.4). Members of the Tec family display a characteristic domain structure
with a unique N-terminal PH domain functionally replacing the Src myristilation
sequence, followed by TH, SH3 and SH2 domains and C-terminal catalytic TK
domain (46). The atypical Txk contains instead of the PH domain, an N-terminal
cysteine string motif with a palmitylation sequence, while the Bmx kinase possess
poorly conserved TH and SH3 domains (Figure 4) (24, 47).
The Tec kinases are involved in signal transduction in response to virtually all
types of extracellular stimuli, including those mediated by growth factor receptors,
cytokine receptors, G-protein coupled receptors, antigen-receptors, integrins and
death receptors. In addition, Tec kinases are regulated by many intracellular tyrosine
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kinases such as Src, Jak, Syk and FAK family members. On the other hand, Tec
kinases regulate many of the major signaling pathways, such as those for PI-3K, PKC
and PLCg, and thereby Tec kinases are also important for cellular responses such as
calcium mobilization, cell growth, differentiation, apoptosis, cytoskeleton
reorganization and cell migration (Figure 5) (for reviews, see (56, 57)). The biological
importance of these kinases is demonstrated by the discovery of a variety of point
mutations in the gene encoding Btk causing immunodeficiency diseases in both
humans and mice (see section 3.7.2) (58).
CC
PH TH ∆SH3 SH2 KD
Y566Y215, Y223
Y551
PH TH SH3 SH2 KD
Y223
PH TH SH3 SH2 KD
Y519Y206
Bmx 675 aa
Btk 659 aa
Tec 631 aa
PH TH SH3 SH2 KD
Y511Y180
SH3 SH2 KD
Y420Y91
Itk 620 aa
Txk 527 aa and 502 aa
100 aa
Figure 4. Protein structure of the Tec family kinases. The target tyrosine residue for Src
family kinases (SFKs) in the TK domain as well as the autophosphorylation tyrosine residue
in the SH3 domain are shown. The Bmx protein has two phosphorylation sites in the SH3
domain of which Y215 is conserved among the Tec kinases (48). Txk is a unique member of
the Tec family in that it has no PH or TH domain, but instead it carries a palmitoylated
cysteine string motif (CC). The lengths of the proteins correspond to the human sequences
(46, 48-55)
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3.1. Expression of mammalian Tec kinases
Genes of the Tec family are differentially expressed, all being found in at least some
hematopoietic cell lineages, but some members are present additionally in other cells
and tissues. The Tec gene, which gives rise to two major isoforms; TecIII and
TecIV/TecA, is the most widely expressed gene of the family. Outside of the
hematopoietic system, Tec transcripts have been detected from several tissues,
including intestine, spleen, placenta, liver, kidney, thymus, bone marrow, testis, heart,
brain, lung and skin (46, 59, 60). In addition, a number of cell types express the Tec
gene, including myeloid, B- and T-cell lineages as well as testicular germ cells,
erythroblasts, hepatocytes and epithelial and endothelial cells (61-65). The Btk gene
has been detected in all hematopoietic cells except T lymphocytes and plasma cells,
although B cells are most severely affected by loss of Btk function (66-68). In
addition, embryonic stem cells express low levels of Btk (69). The Itk gene is
expressed in mast cells, myeloid cells, T lymphocytes and in hematopoietic tissues,
such as the spleen (70, 71). The two isoforms of the Txk protein, are preferentially
found in thymocytes, mast and T cells (47, 72). The Bmx kinase, discussed in section
3.6, is expressed in cells of the monocytic-granulocytic lineage, as well as in certain
endothelial and epithelial cells (17, 18, 25, 26).
3.2. Expression of Tec-like kinases in non-mammalian species
Proteins homologous to Tec kinases have also been found in non-mammalian species.
The expression and function of the fruit fly, Drosophila melanogaster Tec kinase
during embryonic development and adult reproduction is relatively well known (73-
75). Less is known about the function of Tec like kinases in skate fish Raja eglanteria
(76), zebra fish Brachydanio rerio (77), Japanese pufferfish Fugu rubripes
(AJ290422.1; unpublished), chicken Gallus gallus (AF535118.2; unpublished) and
sea urchin Anthocidaris crassispina (78).
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Figure 5. Schematic presentation of signals mediated by Tec kinases. Modified from (53, 56)
3.3. Tec family signaling domains: function, structure and interacting proteins
As described previously, the Tec family kinases possess a typical domain structure; a
PH domain, TH, SH3, SH2 and a C-terminal TK domain (Figures 3 and 4). These
domains have been shown to interact in vitro and/or in vivo with a large number of
proteins, summarized in Figure 6.
3.3.1. PH domain
The hallmark for the Tec family, the PH domain, was initially described in 1993 as an
approximately 100 amino acid long region duplicated in pleckstrin (79-81). Since
then, a large number of PH domain containing proteins has been described, which are
involved in cellular signaling, cytoskeletal organization, regulation of intracellular
membrane transport and modification of membrane phospholipids in organisms from
yeast to mammals (82). The PH domain is one of the most common signaling
domains in the human genome, predicted to be present in 193 different proteins (42).
Typically, PH domains are very poorly conserved, making the identification of
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potential PH domains from the genome sequence difficult. Despite the low degree of
amino acid sequence identity among PH domains (usually 10-30%), all show a similar
structure: a seven-stranded b-sandwich connected by variable loops and capped by a
C-terminal a-helix. The connecting loops play an important role in ligand interactions
and introduce functional variability to this domain (83-85).
PH TH SH3 SH2 KD
SLP-76 Itk
BAP135 Btk
F-actin Btk
Fas Btk PKC Btk, (Bmx)
STAT-3 BmxGbg, aq Btk, Itk
Ga12 Btk
FAK Bmx PTPD1 Bmx
CD2 Itk
EWS Btk
hnRNP-K Itk
Cbl Btk
PLCg Itk
Sab Btk
Sam68 Btk, Itk
Vav Btk
WASP Btk, Itk, Tec
SOCS-1 Itk
SLP-76 Itk
CD28 Itk, Tec
Lyn Btk
Hck Btk
c-Kit Tec
Grb2 Itk
Fyn Btk
Ga12 Btk
Vav Btk, Tec
PLCg ItkBRDG1 Tec
BLINK Btk p85 Itk, Tec
p55 Tec
Caveolin Bmx, Btk
Fas Btk
SOCS-1 Tec
DOK-1 Tec
DOK-1 Itk
IBtk Btk
Rch1a Itk
Figure 6. Schematic representation of Tec family binding partners. Proteins binding to each
homology domain are illustrated (phosphatidylinositol binding to the PH domain and
intra/inter molecular bindings are not shown). The Tec family member(s) reported to bind is
marked in superscript. Modified from (46, 86).
When the PH domain was identified, it was thought to be exclusively a
protein-binding domain. The first PH domain binding proteins reported were the bg
subunits of heterotrimeric G proteins (Gbg) that were shown to interact with b-ARK
(87) as well as with Btk (88). The Gbg subunits have also been suggested to directly
activate the Btk kinase domain (89). In addition to Gbg subunits, also the Gaq and
Ga12 subunits of heterotrimeric G proteins bind to Btk PH domain, resulting in
elevation of Btk kinase activity (90, 91). The PH domains of Tec family kinases have
subsequently been demonstrated to bind a number of different proteins, ranging from
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F-actin (92, 93) and transcription factors such as BAP-135/TFII-1 (94, 95) and
STAT3 (55) to signaling proteins like FAK (96) and membrane anchored receptor
molecules such as the Fas receptor (97). Most of these interactions cause an increase
in the kinase activity and/or an increase in the activity of the interacting partner, but
some negative regulators binding to the PH domain have also been reported. This
latter group includes PKCb1 (98, 99) and IBtk (100). Interestingly, mice deficient in
PKCb isoforms develop an immunodeficiency similar to xid, the result of mutations
in the Btk gene (101) (see section 3.7.2). Another PKC isoform, PKCd inhibits Bmx
phosphorylation and activation of STAT1 (102), presumably by binding to the Bmx
PH domain.
In 1994, Harlan et al. proposed that PH domains might bind to lipophilic
molecules, especially phosphatidylinositols, and thereby function in membrane
localization of the protein (103). Generally, PH domains bind phosphoinositides with
a broad range of specificity and affinity, but in the past decade the list of proteins
binding with high affinity to specific phosphoinositides has grown (104, 105). For
example, the PH domain of Sos, a small GTPase, binds with high affinity to lipid
vesicles containing the negatively charged phospholipid PIP2 (106), while the PH
domains of Tec family kinases show the highest affinity towards phosphoinositides
phosphorylated at the 3-position of the inositol ring, the product of PI-3K (107). A
number of reports have confirmed the importance of PI-3K in plasma membrane
localization and activation of Tec kinases (108-111). Upon PI-3K activation, the Btk
protein is localized to the plasma membrane (112, 113) and Itk is constitutively
plasma membrane localized in Jurkat cells deficient in PTEN, the PI-3K
counteracting lipid phosphatase (114).
3.3.2. TH domain
The PH domain is extended in the Tec kinase family by a region called the TH (Tec
homology) domain, which consists of about 80 residues preceding the SH3 domain.
The TH domain contains a conserved 27 amino acid residue stretch designated the
Btk motif followed by a proline-rich region. The Btk motif has been shown to be
essential for the binding of the Btk PH domain to Gb g(115, 116).
Immunoprecipitation experiments demonstrated that upon Epo and IL-3 stimulation,
the Tec kinase binds to Vav through its TH domain (117). In addition, the TH domain
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is implicated in the regulation of the catalytic activity of Tec kinases by mediating
inter- or intramolecular interactions with the SH3 domain (see section 3.4) (118-122).
3.3.3. SH3 domain
The SH3 domain was first identified as a region of sequence homology in different
signaling proteins (123, 124). Compared with the SH2 domains (section 3.3.4), the
SH3 domain is more widespread. An estimated 143 human proteins contain 182 SH3
domains, while the budding yeast, Saccharomyces cervisiae, have 23 SH3 domain
containing proteins (125). The approximately 60 residue long SH3 domain has been
recognized in very divergent types of proteins, many of which, like the Src and Tec
family kinases, are involved in signal transduction (126). Early studies suggested that
SH3 domains bind to proline-rich sequences with PxxP as a core conserved binding
motif (127). While PxxP seems to be the major binding target for SH3 domains, other
motifs have also been found to bind specifically to SH3 domains. For example, an
interesting, entirely proline-independent interaction has been characterized between
the SH3 domain of SKAP55, an immune cell adaptor, and the peptide motif
RKxxYxxY (128). Similarly, the Itk SH3 domain was shown to bind specifically to
the Itk SH2 domain, which does not contain a sequence that would resembles the
PxxP consensus motif (129).
The structures of various SH3 domains have been solved; all show similar
folds despite a low degree of primary sequence conservation. The SH3 domain
consists of two anti-parallel b-sheets with the conserved residues on one side of the
molecule (130-132). Although the affinity of SH3 domains for their ligands is
generally quite low, studies using degenerate peptide libraries and phage display
libraries have demonstrated that each SH3 domain has a distinct binding preference
(reviewed in (126)). Binding specificity is probably achieved by the interactions
between non-proline residues in the ligand and the two variable SH3 loops (133).
Mutations in SH3 domains of many proto-oncogenes such as c-Src and c-Abl
increase their transforming potential (134, 135). Deletion of, or mutations in, the Btk
SH3 domain increase the transforming potential of Btk E41K mutant without
affecting the kinase activity (136). Although these findings are in conflict with the
current view on the activation of Tec kinases (see section 3.4), they argue that the
major function of the Btk SH3 domain is to regulate protein-protein interactions.
Indeed, Tec family SH3 domains interact with several, mainly hematopoietic signal
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transduction proteins (Figure 6). The Tec SH3 domain is needed for interaction with
the co-stimulatory signal receptor CD28 on T cells (137). Upon CD28 activation, Tec
binds to the proline-rich sequence of the receptor and mediates phosphorylation of the
docking protein Dok-1 and production of IL-2. The SH3 domains of Btk, Itk and Tec
all bind to Wiskott-Aldrich syndrome protein (WASP), which defect is associated
with a hematopoietic disease affecting multiple blood cell lineages (138, 139). In
addition, the Btk SH3 domain has been reported to bind c-Cbl (140), Vav, Sam68,
EWS (141) and the negative regulator Sab (142), but the physiological relevance of
these interactions is not known. In resting T cells, Itk is constitutively associated via
its SH3 domain with PLCg1. However, antibody stimulation of the cells changes the
interaction to one preferentially involving the Itk SH2 domain (143).
An interesting new area of research of Tec family kinases is the regulation of
gene expression within the nucleus. The nuclear import chaperone
Rch1a has been demonstrated to bind to the SH3 domain of Itk, leading to its nuclear
localization (144). The smaller isoform of Txk (145) as well as Btk (146), have also
been located to the cell nucleus, the latter in a nuclear export signal dependent
manner. Taken together, these studies suggest a new function of the Tec kinases as
direct effectors of gene expression or in nuclear processes via nucleocytoplasmic
shuttling.
3.3.4. SH2 domain
Proteins with SH2 domains control a variety of cellular functions, including
phospholipid metabolism, tyrosine phosphorylation and dephosphorylation, gene
expression, protein trafficking and cytoskeletal architecture (147). The SH2 domain
was first identified in the retroviral oncoprotein v-Fps as an approximately 100 amino
acid region. Later a related sequence was found in other proteins, including the Src
tyrosine kinase, leading to the introduction of the Src homology nomenclature and
SH2 domain (SH1 being the catalytic kinase domain) (148). It has been estimated that
the human genome codes for 87 proteins with a total of 95 SH2 domains, while the
Drosophila melanogaster genome codes for 44 SH2 containing proteins. The genome
of the budding yeast, Saccharomyces cervisiae, contains one protein with a predicted
SH2 domain, although detectable tyrosine phosphorylation has not been documented
in this organism (42, 125).
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In vivo, SH2 domains bind to phosphotyrosine (pY) containing sites, both in
activated receptors and in intracellular proteins. The SH2 domains of different
proteins distinguish between different ligand peptides by the sequence context of the
pY residue. While pY binding alone provides about half of the binding energy, the
remainder comes from a series of weak interactions that are distributed between SH2
domain residues and peptide residues C-terminal of the phosphotyrosine residue. The
large energetic contribution of the pY residue to SH2 domain binding strongly favors
phosphorylated as opposed to non-phosphorylated sequences, providing a means for
rapid induction and termination of cell-signaling events (for a review, see (149)).
Typically, SH2 domains show greatest selectivity for the residue immediately after
the pY (residue +1) and the third residue (+3). The only SH2 domain that has been
shown to be strictly selective for the amino acid residue at position +2 is that of the
Grb2 adapter, which only binds to target sequences containing an aspargine at
position +2 (150, 151). Several three-dimensional structures of SH2 domains alone or
in complex with phosphopeptide ligands have been determined (152-157). They show
that SH2 domains consist of a central b-sheet sandwiched between two a-helices. The
N- and C terminal ends of the domain are close to each other, a feature that has been
found also in other homology domains. This might help the protein to maintain the
overall fold while the domains are interacting with other proteins.
The SH2 domains of Tec family kinases have so far been shown to interact
with relatively few proteins (Figure 6). The Btk SH2 domain binds to tyrosine
phosphorylated adaptor protein BLNK/SLP-65 in B cells, while the Itk SH2 domain
interacts with the corresponding adaptor, SLP-76, in T cells. These interactions are
presumably needed for downstream PLCg activation (see section 3.5.1) (158). The
Tec SH2 domain is essential for binding and tyrosine phosphorylation of the docking
protein Dok-1 (159) and BRDG1 (160) as well as PI-3K subunits p85b and p55PIK
(161).
3.3.5. Kinase domain
The catalytic domains of Tec kinases are highly conserved. The amino-terminal lobe
of the Btk kinase domain contains five strands of antiparallel b sheets and one a
helix, the carboxyl-terminal lobe is a four-helix bundle flanked by a short antiparallel
b sheet and four additional helices. The linker region between the N- and C-terminal
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lobes forms a cleft at the ATP binding site. The structure also sheds light into the role
of tyrosine phosphorylation of the conserved residue in the kinase domain during Tec
family kinase activation (see section 3.4) (162).
In addition to their role as catalytic domains, the Tec family kinase domains
function as a protein-binding domain (Figure 6). All Tec kinases contain a highly
conserved caveolin-binding motif in their kinase domain (163). Caveolin is the
principal component of caveolae membranes, which are invaginations of the plasma
membrane that play an important role in many cellular signaling pathways. Both Btk
and Bmx were found to associate with caveolin in vivo leading to a reduction of Btk
tyrosine phosphorylation (163). The Btk kinase domain, together with the Btk PH
domain, binds to the Fas cell death receptor, protecting cells from Fas induced cell
apoptosis (97). The association of Tec SH2 domain with p85b and p55PIK subunits
of PI-3K is dependent on the Tec kinase domain as well (161).
3.4. Activation of Tec kinases by intra- and intermolecular associations
A number of studies have indicated that protein tyrosine kinases are regulated via
intramolecular and/or intermolecular interactions. The first clue came in 1997, when
the crystal structures of Src family kinases (SFKs), Src and Hck were resolved (164,
165). The models confirmed earlier observations that the SH2 domain binds to the
inhibitory phosphotyrosine (Y527 in Src) of the protein (166, 167). The new
surprising finding concerned the function of the SH3 domain. This was not clear,
because the SH3 domain was known to participate in the regulation of the activity of
the protein (168), but the underlying mechanism was not understood. The crystal
structure revealed that the SH3 domain plays a crucial role by interacting with the
linker between the SH2 domain and the catalytic domain. These intramolecular
interactions keep the protein in a locked conformation, thereby blocking the catalytic
activity of the kinase domain and preventing the SH2 and SH3 domains from
interacting with their normal targets (164, 165).
Unlike Src kinases, Tec kinases lack the conserved C-terminal regulatory
tyrosine residue. Instead, Tec kinases have two regulatory tyrosine residues, one in
the activation loop of the kinase domain and one in the SH3 domain (Figure 4).
Results from several studies show that the C-terminal tyrosine residue in the kinase
domain (Tyr551 in Btk) is phosphorylated by SFKs, resulting in a partial activation of
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the Tec kinase and subsequent autophosphorylation of the tyrosine residue in the SH3
domain (Tyr223 in Btk) (54, 55). Phosphorylation of the two regulatory tyrosine
residues, together with association of the PH domain with either phosphoinositols or
protein targets, such as FAK (96), results in the full activation of the protein (Figure
7).
Figure 7. Model for Tec family kinase activation. The three events needed for activation are
marked: 1. Binding of the PH domain to phosphorylated inositol lipids produced by PI-3K
activated by for example a growth factor receptor (left part) or to a binding protein such as
FAK (right part) 2. Phosphorylation of the regulatory tyrosine residue in the kinase domain
by activated SFKs 3. Autophosphorylation of the conserved tyrosine residue in the SH3
domain
Like Src kinases, Tec kinases also undergo intramolecular and intermolecular
interactions. Phosphorylation of the kinase domain tyrosine residue and binding of the
PH domain may function to disrupt these intramolecular associations, allowing the
regulatory domains to bind their substrates. Based on the three-dimensional structure
of the Btk kinase domain, Mao et al, proposed that phosphorylation of Tyr551 leads
to Btk activation by introducing a change in interacting pairs from Glu445/Arg544 to
Glu445/Lys430, causing a relocation of the aC helix of the N-terminal lobe. This
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would enable Glu445 to take part in the catalytic reaction (162). By multidimensional
nuclear magnetic resonance, Andreotti et al. demonstrated an intramolecular
regulatory association between the Itk TH and SH3 domains. Formation of this
intramolecular complex prevents the Itk SH3 domain and the proline-rich region from
interacting with their ligands (118). Later, Brazin et al showed that the SH3 domain of
Itk is also capable of intramolecular association with the adjacent SH2 domain (129).
This may provide a possible mechanism for the displacement of the SH3 and TH
domain binding, a step that might be required for full kinase activation. While Itk
undergoes intramolecular self-association, the Btk TH domain, like Tec, has two
proline-rich sequences in the C-terminus. These undergo asymmetric
homodimerization with the SH3 domain (169). At low protein concentrations a
monomeric species predominates, but changes in the local concentration of Btk, for
example through enrichment at the plasma membrane following activation of PI-3K,
could shift the equilibrium toward dimer formation, affecting the catalytic activity of
Btk (169). Similarly, the SH3 domain of Tec promotes dimerization the protein. The
first proline-rich sequence in the Tec TH domain binds intramolecularly to the SH3
domain, while the second proline-rich sequence is unable to bind intramolecularly and
instead it out competes the first proline-rich sequence, resulting in dimer formation
(132).
Whether the activities of all Tec kinases are regulated in a common way
remains to be seen. The regulatory tyrosine residue in the kinase domain is conserved
throughout the Tec family and all members, except Bmx, contain one or two proline-
rich SH3 ligand sequences in the C-terminus of the TH domain. Txk, however, lacks
the TH domain, while Bmx contains a PxxP motif surrounded by non-conserved
residues. Moreover, the poorly conserved Bmx SH3-like domain contains two
potential autophosphorylated tyrosine residues compared to one in the other Tec
kinases (48). These findings, together with the observations that the mouse Bmx
sequence lacks a major part of the SH3-like domain (Figure 9, (17)), suggests that the
catalytic activity of Bmx and perhaps also other Tec kinases might be regulated in a
family member specific fashion. However, the two major activation steps, membrane
localization (110, 111) and phosphorylation of the regulatory tyrosine residue in the
kinase domain (55) are also needed for Bmx activation.
Niklas Ekman28
3.5. Signal transduction by Tec kinases
3.5.1. Signaling by Tec kinases downstream of activated T and B cell receptors
As described in section 3.3, Tec family kinases associate with a large number of
proteins. Perhaps the best documented downstream function of Tec kinases is to
activate PLCg and the subsequent regulation of intracellular Ca2+ release downstream
of T- and B-cell receptors (TCR and BCR, respectively). Engagement of antigen
receptors causes an activation of PI-3K and SFKs, the latter leading to the activation
of Syk kinases (Syk and ZAP-70). Syk kinases in turn phosphorylate downstream
targets BLNK/SLP-65 in B cells and LAT and SLP-76 in T cells, enabling a complex
of BLNK/SLP-65, PLCg, Vav, Grb2 and SOS to form in B cells and the
corresponding LAT-SLP-76-PLCg-Grb2-GADS-SOS complex in T cells. Formation
of these signaling complexes is critical for the activation of PLCg, which catalyses the
hydrolysis of PIP2 to IP3 and DAG. IP3 functions as a major mediator of Ca2+
mobilization from cytoplasmic storage vesicles while DAG is a well established
activator of PKC (for reviews on PLCg signaling in B and T cells, see (170, 171)).
As discussed above, the first step in antigen receptor signaling is the activation
of SFKs and PI-3K. SFKs phosphorylate and activate in addition to Syk kinases, also
Tec family kinases (see section 3.4). Activated PI-3K produces PIP3, the principal
lipid ligand for Tec family PH domains, and the resulting ligand interaction is needed
for complete PLCg activation (for a review, see (172)). Using biochemical
approaches, Btk SH2 domain was shown to bind directly to tyrosine phosphorylated
BLNK/SLP-65 in B cells, while Itk SH2 domain interacts with SLP-76 adaptor in T
cells (158). The Btk deficient DT40 chicken B cells exhibit a reduction in PLCg2
phosphorylation upon BCR cross linking and a consequent failure to mobilize Ca2+
and generate IP3 (173). This defect can be overcome by overexpression of any Tec
kinase family member (174, 175), suggesting that PLCg function as a general target
for Tec kinases. Itk may directly bind to PLCg (143), while Btk and presumably other
Tec kinases tyrosine phosphorylate PLCg2, causing its activation (176). As will be
discussed in section 3.7.1, mice deficient in Tec family kinases show defects in PLCg
activation and Ca2+ mobilization, further indicating a link between activation of Tec
family kinases and PLCg (174, 177).
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In addition to their function in PLCg activation, Tec kinases may also exert
other functions in the antigen receptor signalosome. For example, they contribute to
the stability of the complex. Txk, which is activated in response to TCR stimulation
(178), phosphorylates the N-terminal region of SLP-76, a region that has previously
been shown to be a ZAP-70 binding target (179). Moreover, the Itk proline-rich
region binds to Grb2 and the linker protein LAT, while the SH3 and SH2 domains
interact cooperatively with Syk-phosphorylated SLP-76 (180).
A third feature of Tec kinases downstream of antigen receptors appears to be
cytoskeletal reorganization. In Jurkat T cells, CD3-induced activation of b1 integrin
mediated adhesion to fibronectin requires Itk kinase activity. Following membrane
translocation, Itk can activate b1 integrins and regulate b-actin polymerization (181).
Regulation of actin cytoskeleton seem to be a general future for Tec kinases as also
Btk and Bmx have been linked to cytoskeletal reorganization (92, 93, 96, 113, 182).
3.5.2. Tec kinases in signaling downstream of other hematopoietic receptors
The list of Tec family activating receptors expressed on hematopoietic cells is
continually growing. Btk is activated through the high affinity IgE receptor (FceR) on
mast cells (183), B cell co-stimulatory receptor CD19 (65), B cell CD72 (184) as well
as by gp130 (185) and receptors for IL-3 (186) and IL-5 (187). Tec becomes
phosphorylated and activated in response to several interleukins and growth factors,
such as IL-3 (188), gp130 (185), SCF (189), G-CSF (190), TPO (191), CD38 in pro-B
cells (65) and co-stimulatory receptors CD3 and CD28 on T cells (137) and CD19 on
B cells (65). Itk is activated through FceR on mast cells (183) and CD2 (192), CD3
(193) and CD28 (194) co-stimulatory receptors on T cells, while Bmx is activated
following IL-3 and G-CSF stimulation of myeloid progenitor cells (111) and IL-6
stimulation of prostate cancer cells (110). So far, the only receptor complex known to
activate Txk is the TCR (178).
3.5.3. Downregulation of Tec kinase activity
The negative regulation of Tec kinases is thought to take place in two different ways.
The activated phosphatases PTEN in T cells or SHIP and PTEN in B cells prevent
further recruitment and activation of Tec kinases following PLCg activation by
removing the PH domain substrate PIP3. In addition, the activity of Tec kinases seems
to be directly downregulated by certain proteins. IBtk is an inhibitor of Btk, which
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binds to Btk PH domain and interfere with Btk-dependent downstream events like
Ca2+ mobilization (100). Several PKC isoforms are known to associate with Btk PH
domain, leading to a decrease in kinase activity (98, 195). In B and mast cells, PKCb
phosphorylates a serine residue in the Btk TH domain causing a decrease in Btk
membrane localization and presumably also its activity (196). As PKC is activated
downstream of PLCg, which in turn is dependent on Btk activity, this mechanism
provides an autoinhibitory loop that turns off Btk catalytic activity off following
PLCg activation. Also Bmx activity is regulated by PKC; in transient transfection
experiments Bmx induced STAT1 activation is downregulated by PKCd (102).
3.5.4. Tec kinases in signal transduction of non-hematopoietic cells
Although at least Tec and Bmx are expressed also outside of the hematopoietic
system (see section 3.1), little is known about the signaling of Tec kinases in non-
hematopoietic cells. Following prolactin stimulation of transiently transfected cells,
Tec associates with and is activated by the prolactin receptor (197). Furthermore, Tec
enhances the activity of the receptor bound guanine nucleotide exchange factor Vav1,
leading to an increase in GTP bound Rac1 (197). This suggests that Tec is involved in
regulating non-hematopoietic cell proliferation and cytoskeletal reorganizations,
target functions of Vav and Rho family members, respectively. The Bmx tyrosine
kinase, which will be discussed in more detail below, is activated by endothelial
specific receptors VEGFR-1 and Tie-2 (18), by TNFR-2 (198) and possibly also by
EGF and TGFa (ligands for EGF receptor), and HRG (ligand for erbB3 and erbB4)
(56).
3.6. The Bmx tyrosine kinase
The Bmx gene (also named Etk for epithelial and endothelial tyrosine kinase (199)),
was originally isolated in 1994 while Tamagnone et al were screening for novel
protein tyrosine kinase genes expressed in human bone marrow (24). Because the
gene was mapped to chromosome Xp22.2, it was called Bmx, Bone Marrow tyrosine
kinase gene in chromosome X. Bmx possesses the same domain structure as the other
members of the family, however, the TH and SH3 domains are poorly conserved. In
the initial study by Tamagnone et al., Bmx mRNA was found in the adult and fetal
heart, while weaker signals could be detected from fetal lung and kidney as well as in
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adult skeletal muscle, placenta, lung, liver, testis ovary and small and large intestines
(24). Like the other members of the family, Bmx was subsequently shown to be
expressed in hematopoietic cells. By RT-PCR, Bmx mRNA was detected in human
neutrophilic granulocytes (25). In mouse granulocytes and monocytes, increased
expression was observed upon cell differentiation (26). Additionally, the Bmx gene is
expressed in certain endothelial and epithelial cells (17, 18). The Bmx protein has
been implicated in several important, and even opposing antagonistic processes such
as apoptosis (111, 175, 200), cell survival and/or proliferation (201-205), cell
differentiation (110, 111), actin reorganization and/or cell migration (96, 182, 198)
and cell tumorgenicity (55, 206) (Figure 8).
Figure 8. Cellular
processes regulated by
Bmx. See the text for
details.
The role of Bmx
in regulating cell
survival and apoptosis is
somewhat contradictory.
In prostate cancer cells,
IL-6 was demonstrated to activate Bmx through PI-3K. Following IL-6 treatment, the
prostate cancer cell line LNCaP undergoes a neuroendocrine-like differentiation,
which is blocked by overexpression of dominant negative Bmx (110). The same cell
line was used by Xue et al. to demonstrate that Bmx protects prostate cancer cells
against photodynamic therapy-induced apoptosis (202). This led the authors to
postulate that Bmx is involved in cell survival and progression of prostate cancer.
Other results also point to a survival role for Bmx. For example, signaling by Bmx,
together with Src and FAK, is needed for androgen independent growth of prostate
cancer cells (204). Bmx has also been found to have anti-apoptotic or survival effects
in other experimental settings; Bmx was recently shown to induce epithelial and
endothelial cell proliferation by upregulating VEGF expression (205). Since VEGF is
a known activator of Bmx (18), these results suggest a functional Bmx-VEGF
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autoregulatory loop. In addition, Bmx is implicated in Ga12/13 induced, RhoA
mediated activation of the serum response factor (SRF) (201, 207). Ga12/13, RhoA
and SRF activation have all been linked to growth factor responses such as cell
proliferation (for a review, see (208)). Contrary to these findings, Bmx has also been
implicated in the induction of cell death. In Btk deficient chicken B cells, Bmx
reconstitutes Btk induced apoptosis (175), while Bmx expression sensitizes the mouse
myeloid progenitor cell line 32D toward apoptosis upon G-CSF treatment (111). Bmx
is also a target for caspase 3 during apoptosis in vivo and in vitro. Following caspase
cleavage, Bmx is converted to a proapoptotic form. The cleavage product containing
the kinase and SH2 domains has a fourfold higher kinase activity than full length
Bmx and this sensitizes prostate cancer cells to apoptosis in response to apoptosis-
inducing stimuli (200).
A newly discovered function of the Tec kinases, and especially for Bmx, is the
regulation of actin reorganization. Btk has been known to associate with F-actin (92)
and to induce cytoskeletal reorganization via activation of Rho-family members
(113), but only recently has the central role of Bmx in the regulation of cell migration
begun to emerge. Chen et al demonstrated that Bmx mediates integrin signaling and
cell migration through binding of the Bmx PH domain to the FERM domain of FAK,
resulting in Bmx activation (96). The interaction between FAK and Bmx is required
for integrin-mediated cell migration of normal as well as metastatic prostate and
mammary cancer cells. In the same study, the expression level of Bmx was found to
be higher in cells with high migratory potential, such as endothelial cells (HUVECs)
and metastatic carcinoma cells (prostatic carcinoma cells PC3M and breast carcinoma
cells MB-435S) when compared to non-metastatic carcinoma cells (prostate
carcinoma cells LNCaP and breast carcinoma cells MCF7) (96). In accordance with
these results, Bmx regulates reorganization of actin filaments in epithelial Pa-4 cells
(182) and it mediates TNFa induced, TNFR-2 dependent, endothelial cell migration
and tube formation (198).
Expression of Bmx is also linked to cellular transformation and progression of
human malignancies. Experiments performed with various cell types showed that
Bmx mediates Src-induced cell transformation by linking Src activity to STAT3
activation. At least in the rat epithelial cell line used, Jak kinases were found to play
only a minor role in v-Src-induced STAT3 activation as a dominant negative Bmx
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mutant nearly completely abolished the STAT3 activation (55). The direct activation
of STAT transcription factors by Bmx is in accordance with previously published
results using transient transfections (102). In breast cancer cell line, Pak1 was found
to be a direct phosphorylation target of Bmx (206). Pak1 stimulates anchorage-
independent growth of breast cancer cells (209) and accordingly, Bmx is required for
proliferation, anchorage-independent growth and tumorgenicity of MCF-7 and MDA-
MB435 breast cancer cells (206).
In hematopoietic cells Bmx is activated by IL-3 and G-CSF receptors, it
regulates granulocytic differentiation of mouse myeloid progenitor cells in culture
(111) and activates STAT transcription factors, which are commonly used for signal
transduction by cytokine receptors (55, 102, 210).
3.7. In vivo role of Tec kinases
The reported roles of Tec proteins in cell survival suggest a rather complex function
for these proteins. For example, Btk prevents Fas induced cell death by binding to the
Fas receptor and thereby blocking FADD interaction (97). Btk is also crucial for B
cell survival, and in the absence of wild-type Btk, B cells undergo apoptotic cell death
in response to anti-IgM stimulation (211). On the other hand, Btk also promotes
apoptosis in murine mast cells (212) and Btk is necessary for radiation-induced
apoptosis of the DT-40 B lymphoma cell line (213). As discussed above, Bmx has
likewise been linked to both cell survival and apoptosis. Such dual functions of the
Tec kinases suggest that the proteins may have different functions in different types of
cells or even in the same cell lineage during different stages of development
(reviewed in (57)). Over the past years, significant progress in understanding the
physiological role of Tec family members has been made using mice lacking
members of the Tec family.
3.7.1. Phenotype of mice deficient in Tec kinases
Knockout (KO) mice of individual Tec family members have been generated, and
additionally two combinatorial mutants, Tec/Btk and Txk/Itk have been published
(18, 214-218). In vivo, the most extensively studied family member so far is Btk. This
is largely due to the immunodeficiency syndrome that is associated with naturally
appearing mutations in the Btk gene, XLA in humans and xid in mice. Mice with a
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single deficiency in Bmx (18), Tec (218) or Txk (217) genes, do not show any major
phenotypic alterations. Itk, however, seems to be required for both proper T cell
development and activation. Mice deficient in Itk have decreased numbers of
thymocytes and reduced proliferation responses of mature T cells (216). Itk also has
an effect on the efficiency of thymocyte maturation, but the gene is not required for
CD4/CD8 differentiation (219). However, signaling by Itk is important during
polarization of CD4 cells, as T cells deficient in Itk are unable to polarize towards a
Th2 phenotype (220). Although Txk deficient mice do not show any major defects, the
Itk/Txk double KO mice have a more severe phenotype compared to Itk single KO
mice (217). The double KOs have considerable defects in TCR responses such as
proliferation in response to anti-CD3 stimulation and IL-2 and IFNg production. In
addition, the double knock out mice show defects in TCR mediated IP3 production,
Ca2+ mobilization and MAPK activation, linking Tec kinases to PLCg activation in
vivo (217). Similar to the Itk/Txk double KO mice, Tec/Btk double deficient mice
also show a more profound phenotype compared to mice deficient only in Tec (with
no obvious phenotype) or in Btk (KO mice or xid mice) (218). Mice lacking both Tec
and Btk genes have a severe block in B cell development and consequently seriously
reduced numbers of peripheral B cells. The response to T cell-dependent antigens is
also impaired in these mice (218). These results suggest that in mice, although not in
humans, Tec can compensate for the absent of Btk and argue for at least a partial in
vivo redundancy of Tec family members.
3.7.2. Tec kinases and diseases: XLA and xid
XLA was first described in 1952 as a primary immunodeficiency disease caused by
the absence of gammaglobulins (221). Some 40 years later, Btk was identified as the
gene mutated in XLA (222, 223). The disease affects approximately 1:200 000 males
and is characterized by a block in differentiation at the transition from pro- to pre-B
cells, leading to a decreased number of B lymphocytes and an almost total lack of
antibody producing plasma cells. As a consequence, immunoglobulin levels in
affected individuals are very low (224). A large variety of mutations in the Btk gene
have been identified in XLA, including deletions, insertions and point mutations in all
homology domains (PH, TH, SH2, SH3 and TK domains). Generally, it is difficult to
correlate Btk expression levels and the clinical and immunological outcome, but the
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majority of the mutations result in a lack of Btk protein expression (58). Information
on Btk mutations causing XLA, has been collected into the BTKbase, available at
http://www.uta.fi/laitokset/imt/bioinfo/BTKbase/ (225).
Mice with defects in Btk, both the KO mice and xid mice with a single amino
acid substitution in the PH domain (R28C), show a similar, but milder phenotype
when compared to XLA. These mice exhibit a partial block of B cell maturation, an
absence of CD5 positive B cells and decreased concentrations of serum IgM and
IgG3. The mice fail to make antibodies against some T-cell-independent antigens, but
they have normal titers of antibodies to T-cell-dependent antigens (224, 226, 227).
These results suggest that in mice, Btk deficiency in part can be rescued by other Tec
kinases. This is in accordance with observations made on Btk/Tec double KO mice,
which show a severe block in early B cell development and a more severe decrease in
B cell numbers, a phenotype more similar to XLA (218). It is however interesting to
note that also mice deficient in other B cell receptor downstream molecules, such as
PLCg (228), p85a (229, 230) BLNK/SLP-65 (231, 232) and PKCb (101), show a
xid-like phenotype, indicating that different requirements for Ca2+ signaling in
developing B cells could account for the phenotypic differences seen in humans and
mice (for a review on the topic, see (227)).
Some successful attempts have been reported to correct the xid phenotype in
mice by gene therapy. Drabek et al. generated transgenic mice in which expression of
the human Btk gene was driven by the murine class II MHC Ea gene locus control
region. When these transgenic mice were mated with mice deficient in Btk, correction
of the xid B cell defects was observed (233). Rohrer and Conley showed that injection
of 25,000 normal cells mixed with 475,000 xid cells in lethally irradiated mice, fully
restored both antibody levels and thymus-independent antibody responses in all
transplanted xid mice (234). This suggest that even inefficient gene therapy may
provide clinical benefit for patients with XLA due to the proliferative and survival
advantage of the normal cells compared to the xid cells. It will be interesting to see
whether this, or any other gene therapy approach in the future will be useful for
treatment of patients with XLA.
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AIMS OF THE STUDY
At the start of the present study, the human Bmx cDNA had recently been cloned
from bone marrow cells. The initial publication by Tamagnone et al (24) indicated
that Bmx could be involved in the biology of hematopoietic cells. In addition, the
tissue distribution of Bmx expression suggested a possible function for Bmx in signal
transduction also outside of the hematopoietic system, but at that time, no activating
receptors or downstream targets were known. At the time of writing this thesis,
approximately 30 articles on the function of Bmx have been published, providing
extensive knowledge on the signaling properties of the protein. However, the overall
role of Bmx in cellular signaling is complex and not fully understood yet.
Our primary goal was to determine the expression pattern of Bmx, and based
on this, to elucidate the role of Bmx signaling in hematopoietic and
endothelial/epithelial cells. The study made use of both cell culture models and in
vivo mice models. The following studies were undertaken in order to achieve these
goals:
1) cloning of the mouse Bmx cDNA (I)
2) determination of the expression pattern of mouse Bmx in non-hematopoietic cells
(I)
3) identifying hematopoietically expressed receptors capable of activating Bmx (II)
4) analysis of the functional consequent of Bmx signaling on granulocytic
differentiation (II)
5) generation and analysis of mice deficient in Bmx  (III)
6) identification of Bmx activating endothelial specific receptors (III)
7) analysis of the in vivo signaling properties of Bmx by generation of transgenic
mice over expressing Bmx in keratinocytes (IV)
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MATERIALS AND METHODS
The materials and methods are described in detail in the original publications, which
are here referred to using Roman numerals.
Antigens Description Reference or source Used in
Rabbit polyclonal antiserum against
human Bmx
(24) IIBmx
Mouse mAb against human Bmx BD Bioscience/
Pharmingen
III
Mouse mAb against human CD31
(PECAM)
Berkeley Antibody
Company
IICD31
Rat mAb against mouse CD31 (PECAM) BD Bioscience/
Pharmingen
IV
CD45 Rat mAb against mouse CD45
(Leukocyte common antigen)
BD Bioscience/
Pharmingen
IV
GFP Mixture of several monospecific rabbit
ant-GFP antibodies
Clontech II
HA Mouse mAb against hemagglutinin tag Covance Research
Products
II-IV
K1 Polyclonal rabbit antiserum against
keratin 1, affinity-purified
Convance Research
Products
IV
K10 Polyclonal rabbit antiserum against
keratin 10, affinity-purified
Convance Research
Products
IV
pTyr Mouse mAb against phosphotyrosine
residue, clone 4G10
Upstate Biotechnology III
Tie-1 Rabbit polyclonal antiserum against
human Tie-1
(235) III
Tie-2 Goat polyclonal antiserum against human
Tie-2
R&D Systems III
VEGFR-1 Rabbit polyclonal antiserum against
human VEGFR-1
Dr Masaburni Shibuya III
VEGFR-2 Rabbit polyclonal antiserum against
human VEGFR-2
Dr Lena Claesson-
Welsh
III
VEGFR-3 Mouse mAb against human VEGFR-3,
clone 9D9
(236) III
Abbreviation: mAb = monoclonal antibody
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Cell lines Description Reference or source Used in
293T Human kidney  epithelial cells expressing
the SV40 T antigen and the transforming
gene of adenovirus 5
American Type
Culture Collection
(ATCC)
II, III
32D Mouse myeloid progenitor cells ATCC II
32DBmxKD Mouse myeloid progenitor cells stably
transfected with KD (kinase dead Bmx
containing a C-term. hemagglutinin tag
II II
32DBmxWT Mouse myeloid progenitor cells stably
transfected with WT Bmx containing a
C-term. hemagglutinin tag
II II
HDMEC Human Dermal Microvascular
Endothelial Cells
PromoCell,
Heidelbegr, Germany
III
HUVEC Human Umbillical Vein Endothelial
Cells
(237) II
LEII Mouse Lung Endothelial cells (238) II
WEHI-3D Mouse lymphoblasts, IL-3 producing ATCC II
DNA vectors Description Reference or source Used in
pcDNA 3
p110-CAAX
PI-3K catalytic subunit Dr Julian Downward II
pcDNA 3.0n
Tie-1
Human full length Tie-1 Dr Yuji Gunji III
pcDNA 3.1
Bmx-∆KD -
GFP
Human Bmx cDNA lacking the kinase
domain fused to a C-terminal GFP tag
II II
pcDNA 3.1
Bmx-∆PH-
GFP
Human Bmx cDNA lacking the
pleckstrin homology domain fused to a
C-terminal GFP tag
II II
pcDNA 3.1
Bmx-E42K-
GFP
Human Bmx cDNA with a E42K
mutation fused to a C-terminal GFP tag
II II
pcDNA 3.1
Bmx-GFP
Full length human Bmx cDNA fused to a
C-terminal GFP tag
II II
pcDNA 3.1
Bmx-R29C-
GFP
Human Bmx cDNA with a R29C
mutation fused to a C-terminal GFP tag
II II
pcDNA
3.1/NT-GFP
Cloning plasmid for construction of C-
terminal GFP fusion proteins
Invitrogen II
pcDNA 3.1z
Tie-1
Human full length Tie-2 (239) III
pcDNA 3.1z
Tie-1*
Human full length Tie-2 with a R849W
activating mutation
(239) III
pcDNA 3.1z
VEGFR-1
Human full length VEGFR-1 (239) III
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pcDNA 3.1z
VEGFR-2
Human full length VEGFR-2 Dr Bruce Terman,
(239)
III
pcDNA 3.1z
VEGFR-3
Human full length VEGFR-3 (239) III
pCI neo
BmxHA
Full length human Bmx cDNA with a C-
terminal hemaglutinin (HA) tag
(102) II, III
pEF-BOS G-
CSFR
Human G-CSFR Dr Shigekazu Nagata II
SignalpIG
hAng-1
Human angiopoietin-1 for secretion into
medium
R&D Systems, II II
Growth
factors
Description Reference or source Used in
hAng-1 Human angiopoietin-1 conditioned 293T
medium
(240), III III
hG-CSF Human Granulocyte-colony stimulating
factor
Drs Riitta Alitalo and
Petri Salven
II
hIL-3 Human interleukin-3 PeproTech II
hVEGF165 Human VEGF 165 splice isoform R&D Systems III
mIL-3 Mouse interleukin-3 Calbiochem
Novabiochem
II
Inhibitors Description Reference or source Used in
Wortmannin Inhibitor of PI-3K Sigma II
LY294002 Inhibitor of PI-3K Sigma II
Methods Used in
b-Galactosidase staining of tissues III, IV
Cell culturing II-IV
Cell transfection II, III
DNA cloning and subcloning I-IV
Flow cytometric analysis of Annexin-V and propidium iodine stained cells II
Generation and analysis of mouse skin wounds IV
Generation of transgenic mice III, IV
Growth factor stimulation II, III
Immunohistochemistry III, IV
Immunoprecipitation III, IV
In situ hybridization I
In vivo tumor growth assay IV
Isolation and analysis of bacteriophage lambda clones I, III
Kinase assay II, III
Lectin perfusion staining III
May-Grünwald Giemsa staining of cytospin preparations II
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Microarray analysis of gene expression IV
MTT assay II
Northern blotting I, II
PCR I, II, IV
RNA extraction II-IV
RT-PCR III, IV
Southern blotting III
Western blotting II-IV
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RESULTS AND DISCUSSION
The main results of the studies are summarized here. The results are presented and
discussed in more detail in the accompanying original publications, which are here
referred to using Roman numerals.
1. CLONING OF MOUSE BMX cDNA AND CHARACTERIZATION OF THE
EXPRESSION PATTERN OF THE GENE (I)
In order to clone the mouse Bmx cDNA, a bacteriophage lambda cDNA library from
12 day p.c. mouse embryo was screened with a human Bmx cDNA probe. One
positive clone containing about 1.7 kb of the open reading frame, but lacking the 5´
sequence, was isolated. The missing 5´ part was subsequently isolated by a PCR
approach using mouse heart cDNA as the template. The isolated cDNA sequence was
found to code for a polypeptide with an overall identity of approximately 91 % to the
human Bmx protein, the mouse protein however lacked a large portion of the SH3
domain (Figure 9). The poorly conserved Bmx SH3 domain indicates that the activity
of the protein might be regulated in a different way when compared to the other
members of the family (see section 3.4). It is also interesting to note that both of the
recently identified tyrosine phosphorylation sites in human Bmx SH3 domain (Y215
and Y223) (48) are in the missing region of the mouse sequence. Whether these
observations have any impact on the regulation of the catalytic activity of Bmx
remains to be seen.
Using a Northern blot containing polyA RNA from various adult mouse
tissues, clear signals were obtained only from the heart and lung. In order to analyse
the source of the signals at the cellular level, we performed in situ hybridizations on
sections of mouse embryos. Starting from day 12.5 of embryogenesis (E12.5), clear
and specific signals could be detected from the heart endocardium and the
endothelium of the dorsal aorta. In addition, other big arteries were positive for Bmx
mRNA. In adult mice, autoradiographic signals were obtained from the heart
endocardium of the left ventricle and from the aorta. These results pointed for the first
time to a relatively specific arterial endothelial expression of Bmx, which later was
confirmed and further expanded ((18), III).
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Figure 9. Amino acid sequence alignment between mouse and human Bmx. In the TH-like
domain, the PxxP motif is boxed, while the conserved residues of the Btk motif are marked
with asterisk. The SFK phosphorylation site (Y556) is also boxed. The line indicates the ATP
binding sequence in the TK domain. The tandemly repeated peptide sequences in human Bmx
are indicated with arrows.
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2. ACTIVATION OF BMX IN HEMATOPOIETIC CELLS AND THE ROLE
OF BMX IN MODULATING GRANULOCYTIC DIFFERENTIATION (II)
The hematopoietic expression pattern of Bmx had recently been established before the
initiation of this work. Kaukonen et al. first showed that Bmx mRNA is detected in
human neutrophilic granulocytes (25). At about the same time, Weil et al.
demonstrated that in mouse bone marrow cells, the granulocytic and monocytic
lineages expressed high levels of Bmx , with increased expression during
differentiation and cell maturation. In contrast to human cells, in mouse cells, Bmx
expression was detected in peripheral blood monocytes and in macrophages, in
addition to the neutrophils (26).
We searched for potential receptors that could activate Bmx in granulocytes,
and found by transient co-transfections experiments that G-CSFR was capable of
stimulating the tyrosine phosphorylation of Bmx. At that time, no other receptors had
been shown to activate Bmx. In order to test the effect of Bmx expression on G-CSF
induced cell signaling, we used the 32D cells. These cells are derived from normal
mouse bone marrow, they are strictly IL-3 dependent and can be induced to undergo
myeloid differentiation in the presence of G-CSF (241). In addition, these cells do not
express endogenous Bmx, which made them suitable for our studies. The 32D cells
were stably transfected with either WT or an inactive K445R (KD) mutant of Bmx.
As expected, G-CSF increased the kinase activity of Bmx in a time and dose
dependent manner, but in addition, also IL-3 was found to strongly increase Bmx
kinase activity. Activation by both cytokines was dependent on PI-3K as both
Wortmanin and LY294002, inhibitors of PI-3K, almost totally abolished the
activation. In addition, using transfected endothelial cells, we could show that Bmx
was translocated to the plasma membrane in response to PI-3K activity.
While both IL-3 and G-CSF control the survival of 32D cells, only G-CSF is
capable of inducing their terminal differentiation. Since Bmx expression is increased
during granulocytic differentiation (26), we analysed the effects of Bmx expression
during cytokineinduced myeloid cell proliferation and differentiation. In the
presence of IL-3, both WT- and KD-Bmx expressing cells proliferated at similar
rates, showing that Bmx expression per se did not affect IL-3-mediated growth or
survival. When the cells were switched to G-CSF containing media, cells expressing
KD-Bmx initiated granulocytic differentiation. In contrast, the WT-Bmx expressing
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cells did not survive in G-CSF containing media and were found to undergo
apoptosis, as judged by staining for annexin-V and chromatin (illustrated in Figure
10).
Figure 10. Bmx modulates cytokine
induced 32D cell differentiation. In the
presence of G-CSF, 32D cells expressing
KD-Bmx differentiate into mature
granulocytes, while WT-Bmx expressing
cells undergo programmed cell death
The differentiation of
hematopoietic progenitor cells in vivo
involves both cell proliferation and
apoptosis. Many cytokines function
both as survival and proliferation
factors, and in the absence of
appropriate cytokines, the progenitor
cells undergo programmed cell death (242). Using the 32D myeloid progenitor cells,
we found that Bmx is involved in maintaining the crucial balance between cytokine-
induced cell survival, proliferation and differentiation. Increased Bmx activity in non-
differentiated progenitor cells may predispose the cells to apoptosis upon G-CSF
stimulation, but not during their proliferation as immature cells. Thus, a
differentiation stage-dependent regulation of Bmx is critical for cell survival. As
endogenous Bmx is expressed in differentiated myeloid cells (26), we hypothesize
that Bmx is involved in functional modulation of differentiated myeloid cells rather
than in regulation of the proliferation and differentiation of the precursor cells. As
discussed earlier, Tec kinases, including Bmx, are implicated in both pro-apoptotic
and anti-apoptotic signaling. How these seemingly conflicting signals are carried out
is not known, but it has been suggested that the Tec family kinases may have different
functions in different types of cells or even in the same cell lineage during different
stages of development and differentiation (for a comprehensive review on the dual
role of Btk in pro- and anti-apoptotic signaling, see (57)).
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3. GENERATION OF MICE DEFICIENT IN BMX AND ANALYSIS OF BMX
PROMOTER ACTIVITY IN VIVO (III)
In this study, we explored the biological function of Bmx by creating mice deficient
in the Bmx gene. This was done by replacing the first coding exon of the Bmx gene
with the LacZ gene encoding b-galactosidase. Mice of all genotypes were born at the
expected ratios, they were fertile and had normal life spans. Despite careful
histological and functional analyses, no obvious defects due to the loss of the Bmx
gene could be detected. This model however allowed a detailed study of Bmx
expression in arterial endothelial cells of fetal and adult tissues.
The b-galactosidase activity of the Bmx gene-targeted mice was used to assess
the sites of Bmx promoter driven LacZ expression. No staining was observed at
embryonic day 10.5 (Figure 11A). However, starting around E12.5, strong staining of
the endocardium of the heart and the endothelium of large arteries was seen (Figure
11B). At this stage, all major arteries showed clear staining from the endothelial cells,
while venous endothelia were negative. Later during embryonic development, the
expression pattern was the same as in E12.5 embryos, except that now also more
peripheral branches of the arteries were b-galactosidase positive. The only venous
endothelia that showed weak signals was the superior and inferior venae cavae close
to the site where they enter the heart. In adult mice, arteries throughout the body
showed strong b-galactosidase activity (Figure 11C, coronary arteries), whereas
capillaries were negative. Some stainings were also detected outside of the
cardiovascular system; strong signal was present in the Hassalls corpuscles in the
medulla of the thymus. Additional expression was found in the mucous membrane of
the tongue where some epithelial cells in the basal layer expressed b-galactosidase.
The expression became weaker when the cells keratinized and moved upwards.
The arterial endothelial specific gene expression of Bmx suggested that the
protein could be activated by endothelial specific receptors. These receptors fall into
two major families, the Tie receptors (Tie and Tie-2/Tek) and the VEGF receptors
(VEGFR-1, -2 and 3). The Tie-2 receptor is activated by angiopoietin-1 and -4,
while PlGF and VEGFs are ligands for VEGF receptors. So far, no activating ligand
has been identified for Tie-1 (reviewed in (243, 244)). When Bmx was coexpressed in
human 293T cells together with Tie-1, Tie-2, VEGFR-1, VEGFR-2 or VEGFR-3,
only Tie-2 and VEGFR-1 induced a significant increase in Bmx catalytic activity and
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phosphotyrosine content. As anticipated, stimulation of human primary microvascular
endothelial cells with angiopoietin-1 or VEGF increased the kinase activity of
endogenous Bmx, demonstrating that also endogenous Tie-2 and VEGF receptors
activate Bmx.
Figure 11 . b -
galactosidase stainings
of embryonic and adult
tissues. A. No signal
could be detected from
E10.5 embryos. B. At
E12.5, all major
arteries were positive.
C. Strong signals could
be detected from the
coronary arteries of the
adult heart (arrow) as
well as from the
auricles (asterisk).
A=aorta,
IA=intercostal arteries,
ICA=internal carotid artery, UA=umbilical artery, VA= vertebral artery.
In conclusion, we demonstrated that Bmx is almost exclusively expressed in
arterial endothelium both during embryogenesis and in adult tissues. Among the
arterial specific genes identified (Table 1), Bmx is the first intracellular tyrosine
kinase. Once isolated, the Bmx promoter could be used for driving transgene
expression in arterial endothelial cells, which is of interest for example in the field of
atherosclerosis research. In addition to studying the expression pattern of Bmx, we
also found that endothelial Tie-2 and VEGFR-1 are able to activate Bmx. Although
we did not look into the route of Bmx activation, it is likely that Tie-2 and VEGFR-1
activate Bmx through PI-3K as both these receptors have been shown to signal via PI-
3K (245, 246). PI-3K has previously been established as an important mediator of Tec
family kinase activation, including Bmx (see section 3.3).
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4. ANALYSIS OF THE IN VIVO FUNCTION OF BMX IN EPITHELIAL
CELLS OF THE SKIN (IV)
In order to study the vascular functions in the Bmx-KO mice generated in III, we
analysed skin wound healing in these mice. All growing vessels, both in physiological
angiogenesis (wound healing) and in pathological angiogenesis (tumor angiogenesis)
turned out to be negative for Bmx-b-galactosidase staining. In contrast, keratinocytes
migrating over the wound strongly upregulated Bmx (Figure 12). This observation
came as a surprise as Bmx had not been linked at that time to cell migration. In
contrast, today the vital role of Bmx signaling in cell migration is well established,
primarily from the work of Chen et al. and Pan et al. (96, 198). Surprisingly, we could
however not detect any significant difference in the rate of wound healing when
comparing wildtype (WT) mice and mice deficient in the Bmx gene. We therefore
decided to generate mice over expressing Bmx in keratinocytes and analyse if these
mice show any phenotypic alternations in skin histology.
Figure 12. Upregulation of Bmx-
LacZ in migrating keratinocytes
during wound healing.
This was achieved by placing Bmx under the control of the human keratin 14
promoter. Analysis of the K14-Bmx transgenic (TG) mice revealed a number of
defects, such as scaling of the skin throughout the lifespan of the mouse, poor hair
coverage, parakeratosis, thicker epidermis compared to WT littermates and an
increased dermal cellularity, at least in part due to leukocyte infiltration. In addition,
the K14-Bmx TG mice showed an abnormal vasculature in the skin, presumably due
to inflammatory angiogenesis, with larger and more tortuous vessels. TG mice also
showed a significant acceleration of wound healing compared to WT mice. In order to
find a molecular explanation for the observed phenotype, we compared the gene
expression patterns of newborn TG and WT skin using high throughput gene
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expression analysis. For this purpose Affymetrix oligonucleotide microarrays, which
contain sequence from about 6000 known mouse genes and 6000 expressed sequence
tags (ESTs) were hybridized with RNA extracted from the back skin of the newborn
mice. We identified 41 genes that were reproducibly upregulated and three genes that
were downregulated more then four fold in the TG mice when compared to the WT
littermates. The most striking differences were detected in genes that encode for
inflammatory cytokines, such as IL-6 and chemokines like CXCL1 and CXCL5. We
also saw strong upregulation of inflammation-associated endothelial selectin and
cyclo-oxygenase 2, as well as of keratin 6 and keratin 16 indicating high turnover of
the keratinocytes. From these microarray studies, we conclude that Bmx induces
keratinocyte proliferation and secretion of inflammatory cytokines, thus confirming
the histological findings at the gene expression level.
In conclusion, we could show that Bmx overexpression in keratinocytes
induces a phenotype characterized by proliferation and scaling of the skin and
induction of inflammation and angiogenesis. It is interesting to note that despite the
ability of Bmx to upregulate VEGF in both endothelial and epithelial cells (205), we
were unable to detect differences in VEGF expression levels by microarray
hybridizations, Northern blotting or RT-PCR. These findings strongly suggest that the
angiogenic phenotype was not due to increased VEGF expression, but rather due to
expression of other angiogenic factors involved in inflammation, such as IL-6 and
CXCL1. Cell proliferation, migration and angiogenesis are processes closely linked to
the development, progression and metastasis of tumors. Our study, together with
previously published findings (55, 206), suggests that Bmx could be involved in these
processes, but it remains to be seen whether Bmx expression also has an impact on
tumor progression in vivo.
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CONCLUDING REMARKS AND FUTURE PERSPECTIVES
The sequencing of the human genome has revealed that up to ~20% of the ~32.000
human genes encode proteins involved in signal transduction (38). One important
group of these signaling proteins is the group protein tyrosine kinases, which are
involved in regulation of a great variety of cellular processes. Under normal
conditions, their activities are tightly regulated, but mutations may result in
deregulated kinase activity and malignant transformation of the involved cells.
Cancer, however, does not necessarily arise because of increased cell proliferation.
Rather, the important aspect is the balance between cell survival, cell proliferation,
and cell differentiation on one hand, and programmed cell death (apoptosis) on the
other hand. Members of the Tec family of intracellular tyrosine kinases are involved
in signaling for all these processes (Figure 8; Bmx). Tec kinases, the second largest
family of NRTKs, transmit signals from all classes of cell surface receptors (Figure 5)
and interact through the five homology domains (Figures 4 and 6) with all known
families of NRTKs (Figure 6).
This thesis work was initiated with the goal to elucidate the expression pattern
and signaling properties of one specific member of the Tec family, the Bmx TK.
Some years before starting the project, the human cDNA for Bmx had been isolated,
but at that time, almost nothing was known about Bmx expression pattern, and
nothing concerning the roles of Bmx in cellular signaling. The work described in this
thesis addressed these questions by several means. Following cloning of the mouse
Bmx cDNA (I), the expression profile of the gene was defined (I, III). We also
identified four receptors activating Bmx, two expressed in endothelial cells (III) and
two in hematopoietic cells (II) and showed that Bmx expression influenced the
signaling for granulocytic differentiation (II). In order to understand the role of Bmx
signaling in vivo, two mouse models were generated, one where the Bmx gene was
inactivated by homologous recombination (III) and one where Bmx was
overexpressed in the skin epidermis (IV). From these in vivo models we concluded
that the function of the Bmx gene is replaceable. Mice lacking a functional Bmx gene
did not have any major phenotype, most probably due to redundancy between the five
members of the Tec family (III). On the other hand, overexpression of Bmx in the
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skin of transgenic mice induced a severe phenotype, suggesting that too high Bmx
expression might be detrimental (IV).
As described in this thesis, Tec family members can potentially interact with
numerous cellular factors and regulate even seemingly opposite cellular processes.
Yet, in a given cell there must be strict rules for the binding specificity and the
cellular outcome of the signaling. How this is achieved is not known, but at least in
part, the outcome of the Tec family kinase signaling seems to depend on the cell type
and perhaps also on the differentiation stage of the given cell (57). This also holds
true for the Bmx kinase, which regulates cell survival, differentiation, migration,
apoptosis and transformation. A big challenge for future research in the Tec family is
to understand in detail the biochemical pathways regulated by Tec kinases, as well as
the exact molecular mechanisms by which the catalytic activity of these proteins is
regulated. What comes to Bmx, both results from our own studies (IV) as well as
results published by other groups (55, 206) suggest a role for Bmx in the progression
of tumors. This is an interesting hypothesis that need to be addressed by in vivo
models.
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